Key Stats for Novo Nordisk Stock
- Current Price: $44.19
- Target Price (Mid): ~$72
- Street Target: ~$47
- Potential Total Return: ~64%
- Annualized IRR: ~11% / year
- Earnings Reaction: +0.09% (5/6/26)
- Max Drawdown: -56.46% (3/30/26)
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Novo Nordisk (NVO) is one of the most debated pharmaceutical stocks in the world right now, and not for good reasons. At $44.19, the stock sits roughly 46% below its 52-week high of $81.44, after a stretch that included a CagriSema trial miss, back-to-back guidance cuts, and a Goldman Sachs downgrade to Neutral with a $41 price target in March 2026. The market has made its verdict: Novo is a show-me story.
What the market may be missing is what the last 60 days actually showed. The Q1 2026 earnings call on May 6 revealed that 80% of Wegovy pill users had never taken a GLP-1 drug before, meaning the pill is expanding the market, not cannibalizing it. That same call surfaced a Phase 3 sickle cell disease breakthrough that no drug in its class had previously achieved. Then on May 22, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), the EU body that recommends drug approvals, backed both the Wegovy pill and the higher-dose Wegovy HD 7.2 mg injectable for Europe. NVO closed up 1.28% that day.
The question is whether any of this is enough to shift the trajectory or whether 2026 pricing headwinds are deep enough to swallow every positive.
The Wegovy Pill Is Not Stealing Patients. It Is Finding New Ones.
The most important number from the Q1 2026 earnings call was not in the income statement. It came from Jamey Millar, EVP of U.S. Operations: close to 80% of Wegovy pill users are GLP-1-naive patients, people who had never used a GLP-1 (glucagon-like peptide-1, a hormone that regulates appetite and blood sugar) drug before.
That matters because the central bear case against the oral launch was cannibalization: the fear that patients would simply switch from the injectable to the pill and compress Novo’s revenue per patient without growing the market. Millar addressed it directly: “We see close to 80% of Wegovy pill users are GLP-1 treatment-naive patients. We also see patients coming to the Wegovy pill from competitor products with limited cannibalization from injectable Wegovy.”
The prescription numbers back it up. The Wegovy pill generated 1.3 million total prescriptions in its first full quarter, with weekly scripts reaching 207,000 by mid-April, per Millar on the earnings call. Per CFO Karsten Knudsen, Q1 Wegovy pill sales reached approximately DKK 2.3 billion, of which around $150 million (USD) represented initial pipeline fill with wholesalers and pharmacies. The Wegovy brand now holds around 65% of new-to-brand prescription share in the U.S. anti-obesity market, per Millar, a share the franchise had not held before the pill’s arrival.
CEO Maziar Doustdar was blunt on pricing: “We have priced this product perfectly correct.” He cited 2 million scripts in 16 weeks and 200,000-plus weekly scripts despite Eli Lilly launching its rival oral obesity pill Foundayo in April. He acknowledged prices will eventually need to fall as Novo scales to a much broader patient population, but was clear that the current price is right for where the volume curve sits today.
The reimbursement setup is also improving faster than expected. By the end of Q1, all three of the largest pharmacy benefit managers (PBMs, companies that administer drug benefits for insurers) had added Wegovy pill to their standard formularies at parity with the injectable, which positions the reimbursed channel to grow materially through the rest of 2026 as the current self-pay-heavy mix normalizes.
See historical and forward estimates for Novo Nordisk stock (It’s free!) >>>
The Pipeline Is Broader Than One Trial Result
The market priced Novo as though CagriSema’s REDEFINE 4 trial miss erased everything else in the pipeline. It did not.
CagriSema, a fixed-dose combination of semaglutide and cagrilintide (a long-acting amylin analog that targets appetite through a different pathway than GLP-1s), was filed with the FDA in December 2025 based on REDEFINE 1 and REDEFINE 2 data. An FDA decision is expected by late 2026, with a potential launch in 2027. Chief Scientific Officer Martin Holst Lange was clear on the Q1 call: “We remain excited about the profile of CagriSema and prospect of launching soon given the strong weight loss profile as well as the broader cardiometabolic effects observed.” A higher-dose Phase IIIb trial is also set to initiate in Q2 2026.
Beyond CagriSema, Novo is advancing zenagamtide (previously known as amycretin), an oral next-generation obesity candidate, through its AMAZE Phase 3 program. Multiple AMAZE trials are underway covering obesity, sleep apnea, and knee osteoarthritis. Lange confirmed AMAZE incorporated the key dosing learnings from CagriSema, and that early titration data from the ongoing REDEFINE 11 trial suggests the revised approach is working.
Then there is Etavopivat, Novo’s drug for sickle cell disease (an inherited blood disorder in which malformed red blood cells block blood vessels, causing severe pain episodes and organ damage). The HIBISCUS Phase 3 trial made Etavopivat the first drug in its class to meet both co-primary endpoints: a 27% reduction in painful vaso-occlusive crisis episodes versus placebo, and a hemoglobin response in 48.7% of patients versus 7.2% in the placebo group. Novo plans to file for U.S. regulatory approval in Q4 2026.
Doustdar tied it together on the call: the goal is to “have multiple legs to stand on so we can drive growth short, medium and long term.”
What the Valuation Actually Says
At $44.19, NVO trades at 12.90x NTM P/E and 9.80x NTM EV/EBITDA, per TIKR’s Multiples data. For context, per TIKR’s Competitors page: Eli Lilly (LLY) trades at 28.64x NTM P/E and 22.57x NTM EV/EBITDA, Roche at 16.16x NTM P/E, and Novartis at 17.05x NTM P/E. All three carry a premium to NVO despite none of them running a drug with 200,000-plus weekly prescriptions in the world’s largest pharmaceutical market.
The underlying business metrics are not broken. Per TIKR, the LTM gross margin is 83.2%, the LTM EBIT margin is 49.3%, and the return on equity is 71.4%. These are the numbers of a company under pricing pressure in a transition year, not a structural collapse.
And 2026 is genuinely a transition year. Per TIKR’s consensus estimates, revenue is projected to fall to approximately DKK 292 billion from DKK 309 billion in 2025, with net income margins compressing to around 33%. The headwinds are real: the Most-Favored-Nation pricing agreement with the U.S. administration, semaglutide patent expiries in select international markets, and reduced Medicaid coverage for obesity medications all outlined by Knudsen on the Q1 call as baked into guidance.
But per TIKR’s forward estimates, revenue is projected to recover from 2027 onward. Consensus free cash flow is estimated at around DKK 74 billion in 2027 and approaching DKK 97 billion by 2030, per TIKR. The NTM dividend yield sits at 4.2%, per TIKR, the highest level in years, offering investors an income cushion while the recovery plays out.
See how Novo Nordisk performs against its peers in TIKR (It’s free!) >>>
TIKR Advanced Model Analysis
- Current Price: $44.19
- Target Price (Mid): ~$72
- Potential Total Return: ~64%
- Annualized IRR: ~11% / year
See analysts’ growth forecasts and price targets for Novo Nordisk stock (It’s free!) >>>
The TIKR mid-case uses a revenue CAGR of around 6% through 2030. The two primary growth drivers are global oral Wegovy scaling the U.S. reimbursed ramp plus international launches beginning in H2 2026 and a CagriSema contribution from 2027, pending FDA approval. The margin driver is operating leverage as reimbursed volume grows, with a mid-case net income margin of approximately 33%, supported by Novo’s DKK 8 billion company-wide cost transformation program confirmed on the Q1 call.
The upside is approximately 64% total return, or around 11% annualized through December 31, 2030. The downside: a prolonged pricing war that compresses Wegovy margins faster than volume can offset, combined with CagriSema failing to gain commercial traction. Worth noting: Goldman Sachs’ $41 price target issued at the time of their March downgrade is already below where the stock trades today. Nine of 15 analysts tracked by TIKR remain at Hold, leaving meaningful room for sentiment to shift if catalysts land.
Conclusion
The sharpest near-term inflection point is the FDA’s CagriSema decision, expected by late 2026. Approval shifts the story from a single-product, pricing-pressured company to a portfolio with injectable GLP-1s, an oral obesity drug, and a next-generation combination therapy. Before that, the Q3 2026 readout from the ZEUS cardiovascular trial for Ziltivekimab adds a separate binary catalyst.
What good looks like: CagriSema approved, Wegovy pill weekly scripts above 250,000, and at least two EU market launches before year-end. What bad looks like: an FDA rejection or delay for CagriSema, Foundayo closing the prescription gap faster than expected, and international pricing coming in below expectations.
The pessimism is priced in at 12.9x forward earnings. Whether the recovery is too will be clear by Q4 2026.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in Novo Nordisk?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Novo Nordisk, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Novo Nordisk alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Novo Nordisk on TIKR Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
